Vistin Pharma ASA
OSE:VISTN
Intrinsic Value
The intrinsic value of one VISTN stock under the Base Case scenario is 20.8 NOK. Compared to the current market price of 23.6 NOK, Vistin Pharma ASA is Overvalued by 12%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Vistin Pharma ASA
Fundamental Analysis

Revenue & Expenses Breakdown
Vistin Pharma ASA
Balance Sheet Decomposition
Vistin Pharma ASA
Current Assets | 143.2m |
Cash & Short-Term Investments | 12.8m |
Receivables | 53.7m |
Other Current Assets | 76.7m |
Non-Current Assets | 241.8m |
Long-Term Investments | 12.2m |
PP&E | 229.6m |
Other Non-Current Assets | 1k |
Free Cash Flow Analysis
Vistin Pharma ASA
NOK | |
Free Cash Flow | NOK |
Earnings Waterfall
Vistin Pharma ASA
Revenue
|
429.5m
NOK
|
Cost of Revenue
|
-150m
NOK
|
Gross Profit
|
279.5m
NOK
|
Operating Expenses
|
-194.2m
NOK
|
Operating Income
|
85.3m
NOK
|
Other Expenses
|
-22.5m
NOK
|
Net Income
|
62.8m
NOK
|
VISTN Profitability Score
Profitability Due Diligence
Vistin Pharma ASA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Vistin Pharma ASA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
VISTN Solvency Score
Solvency Due Diligence
Vistin Pharma ASA's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Vistin Pharma ASA's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VISTN Price Targets Summary
Vistin Pharma ASA
Dividends
Current shareholder yield for VISTN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one VISTN stock under the Base Case scenario is 20.8 NOK.
Compared to the current market price of 23.6 NOK, Vistin Pharma ASA is Overvalued by 12%.